Director Appointment

RNS Number : 8542D

Advanced Oncotherapy PLC

03 May 2013

 



3 May 2013

ADVANCED ONCOTHERAPY Plc

("Advanced Oncotherapy" or "the Company")

Director Appointment

Advanced Oncotherapy is pleased to announce the appointment of Dr Sneh Khemka as Chief Operating Officer and a member of the board of AVO.

Most recently Sneh Khemka, aged 37, was Director of Healthcare Development for Bupa Group.  His work included new business development, M&A and big data projects.

Prior to this, Sneh was Medical Director for Bupa International, and interim Chief Medical Officer for Bupa Group. In these capacities he was responsible for large teams in a variety of functions, including insurance underwriting, clinical governance, emergency medical assistance, hospital quality contracting and health information.

Sneh originally trained as a surgeon, specialising in ophthalmology, with an interest in ocular oncology.  He continues clinical practice as a radio doctor, where he has a popular weekly call-in show on London's LBC.  He also works as an expedition medic, supporting people undertaking challenges around the world.

Sneh has previously advised and acted for a number of private equity houses in the UK and Europe.  He is also a non-executive director of the Joint Commission International, the US-based leading hospital accreditation authority.  In 2013, Sneh was awarded an honorary Membership to the Faculty of Public Health in recognition of his contributions to the field.

Current Directorships	Past Directorships
Dundonald Student Property Investments LLP	None
The Inspire and Achieve Foundation

There is no further information required to be disclosed under paragraph (g) of Schedule 2 of the AIM Rules.

Commenting on the appointment, Dr Michael Sinclair, Chief Executive said "Sneh's experience, energy and enthusiasm will significantly enhance our already talented senior management team. We very much look forward to working with him."

Dr Sneh Khemka comments, "I'm very privileged to be joining AVO at this accelerated stage of its development. I truly believe that AVO can bring technology to the worldwide market that will change the face of cancer radiation therapy as we know it."

For further information, please visit www.advancedoncotherapy.comor contact:

Michael Sinclair, Chief Executive	Sandy Jamieson	Jon Levinson	Simon Hudson
Advanced Oncotherapy Plc	Libertas Capital Corporate Finance Ltd	Peterhouse Corporate Finance	Tavistock Communications
	(NOMAD & Joint Broker)	(Joint Broker)	(Financial PR & IR)
[phone]	[phone]	[phone]	[phone]

About Advanced Oncotherapy Plc

·     AVO is a provider of internationally endorsed radiation technology for advanced, cost effective and patient-focused cancer treatments which are clinically superior to those currently available.

·     AVO's acquisition of ADAM, the first CERN spin-off company in the UK, focuses on compact linear accelerators for proton beam therapy and conventional radiotherapy which will dramatically reduce the cost of delivering enhanced radiotherapy treatments for many types of solid tumour cancers.

·     AVO's exclusive mobile service for intraoperative radiotherapy (IORT) and high dose electronic brachytherapy provides therapeutic radiation treatments on demand with minimal toxicity to surrounding healthy tissue without the complex handling, resource logistics and costs associated with using radioactive isotopes resulting in greater cost effectiveness and increased  patient convenience.

·     AVO with its associate company, Advanced Proton Solutions (APS) is building the first comprehensive proton beam therapy centre in the UK to treat both NHS and private patients which will provide improved outcomes and lower side effects for appropriately selected paediatricand adult cancers.

 

END

 

 

BOAATMPTMBIMMLJ